Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure

M. A. Perrella, L. L. Aarhus, D. M. Heublein, J. A. Lewicki, John C Jr. Burnett

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Atrial natriuretic factor (ANF) is a circulating 28-amino acid peptide that functions in the regulation of sodium homeostasis and vascular tone. ANF metabolism occurs via degradation by neutral endopeptidase 24.11 and binding to the ANF clearance receptor (ANFR-C). The present study was performed on anesthetized dogs, normal (control) and with experimental congestive heart failure (CHF), and was designed to investigate the ability of an ANF ligand specific for ANFR-C [C-ANF-(4-23)] to increase plasma ANF and also to evaluate the influence of ANFR-C on regional pulmonary and renal ANF clearances. C-ANF-(4-23) increased plasma ANF in controls (51 ± 15 to 123 ± 39 pg/ml; P < 0.05) and further increased plasma ANF in CHF dogs (242 ± 30 to 327 ± 34; P < 0.05), demonstrating that ANFR-C plays a significant role in the overall metabolism and clearance of ANF, even with chronically elevated ANF. Infusion of C-ANF-(4-23) produced a marked decrease in ANF pulmonary clearance (P(CL)ANF) in controls (1,018 ± 405 to -286 ± 383 ml/min; P < 0.05); however, P(CL)ANF was not altered by the ANF ligand in CHF dogs [-137 ± 174 to -106 ± 226 ml/min; not significant (NS)], suggesting an occupancy of ANFR-C or a downregulation of this receptor with chronically elevated plasma ANF. ANF renal clearance (R(CL)ANF) was not altered in either group by C-ANF-(4-23) infusion. Lack of change in P(CL)ANF and R(CL)ANF with ligand infusions during CHF suggests that the plasma ANF increase produced by C-ANF-(4-23) is related to an altered peptide clearance at sites other than the lung or kidney. This study demonstrates the contribution of ANFR-C to metabolism and clearance ANF during CHF and demonstrates cardiovascular and renal responses to C-ANF-(4-23) infusion in this pathophysiological condition characterized by elevated endogenous ANF.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume265
Issue number1 34-1
StatePublished - 1993

Fingerprint

Atrial Natriuretic Factor Receptors
Atrial Natriuretic Factor
Heart Failure
Kidney
Dogs
Ligands
Lung

Keywords

  • pulmonary clearance
  • renal clearance

ASJC Scopus subject areas

  • Physiology

Cite this

Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure. / Perrella, M. A.; Aarhus, L. L.; Heublein, D. M.; Lewicki, J. A.; Burnett, John C Jr.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 265, No. 1 34-1, 1993.

Research output: Contribution to journalArticle

@article{a4d9028c6e5147a5aa715f0243800e3d,
title = "Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure",
abstract = "Atrial natriuretic factor (ANF) is a circulating 28-amino acid peptide that functions in the regulation of sodium homeostasis and vascular tone. ANF metabolism occurs via degradation by neutral endopeptidase 24.11 and binding to the ANF clearance receptor (ANFR-C). The present study was performed on anesthetized dogs, normal (control) and with experimental congestive heart failure (CHF), and was designed to investigate the ability of an ANF ligand specific for ANFR-C [C-ANF-(4-23)] to increase plasma ANF and also to evaluate the influence of ANFR-C on regional pulmonary and renal ANF clearances. C-ANF-(4-23) increased plasma ANF in controls (51 ± 15 to 123 ± 39 pg/ml; P < 0.05) and further increased plasma ANF in CHF dogs (242 ± 30 to 327 ± 34; P < 0.05), demonstrating that ANFR-C plays a significant role in the overall metabolism and clearance of ANF, even with chronically elevated ANF. Infusion of C-ANF-(4-23) produced a marked decrease in ANF pulmonary clearance (P(CL)ANF) in controls (1,018 ± 405 to -286 ± 383 ml/min; P < 0.05); however, P(CL)ANF was not altered by the ANF ligand in CHF dogs [-137 ± 174 to -106 ± 226 ml/min; not significant (NS)], suggesting an occupancy of ANFR-C or a downregulation of this receptor with chronically elevated plasma ANF. ANF renal clearance (R(CL)ANF) was not altered in either group by C-ANF-(4-23) infusion. Lack of change in P(CL)ANF and R(CL)ANF with ligand infusions during CHF suggests that the plasma ANF increase produced by C-ANF-(4-23) is related to an altered peptide clearance at sites other than the lung or kidney. This study demonstrates the contribution of ANFR-C to metabolism and clearance ANF during CHF and demonstrates cardiovascular and renal responses to C-ANF-(4-23) infusion in this pathophysiological condition characterized by elevated endogenous ANF.",
keywords = "pulmonary clearance, renal clearance",
author = "Perrella, {M. A.} and Aarhus, {L. L.} and Heublein, {D. M.} and Lewicki, {J. A.} and Burnett, {John C Jr.}",
year = "1993",
language = "English (US)",
volume = "265",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "1 34-1",

}

TY - JOUR

T1 - Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure

AU - Perrella, M. A.

AU - Aarhus, L. L.

AU - Heublein, D. M.

AU - Lewicki, J. A.

AU - Burnett, John C Jr.

PY - 1993

Y1 - 1993

N2 - Atrial natriuretic factor (ANF) is a circulating 28-amino acid peptide that functions in the regulation of sodium homeostasis and vascular tone. ANF metabolism occurs via degradation by neutral endopeptidase 24.11 and binding to the ANF clearance receptor (ANFR-C). The present study was performed on anesthetized dogs, normal (control) and with experimental congestive heart failure (CHF), and was designed to investigate the ability of an ANF ligand specific for ANFR-C [C-ANF-(4-23)] to increase plasma ANF and also to evaluate the influence of ANFR-C on regional pulmonary and renal ANF clearances. C-ANF-(4-23) increased plasma ANF in controls (51 ± 15 to 123 ± 39 pg/ml; P < 0.05) and further increased plasma ANF in CHF dogs (242 ± 30 to 327 ± 34; P < 0.05), demonstrating that ANFR-C plays a significant role in the overall metabolism and clearance of ANF, even with chronically elevated ANF. Infusion of C-ANF-(4-23) produced a marked decrease in ANF pulmonary clearance (P(CL)ANF) in controls (1,018 ± 405 to -286 ± 383 ml/min; P < 0.05); however, P(CL)ANF was not altered by the ANF ligand in CHF dogs [-137 ± 174 to -106 ± 226 ml/min; not significant (NS)], suggesting an occupancy of ANFR-C or a downregulation of this receptor with chronically elevated plasma ANF. ANF renal clearance (R(CL)ANF) was not altered in either group by C-ANF-(4-23) infusion. Lack of change in P(CL)ANF and R(CL)ANF with ligand infusions during CHF suggests that the plasma ANF increase produced by C-ANF-(4-23) is related to an altered peptide clearance at sites other than the lung or kidney. This study demonstrates the contribution of ANFR-C to metabolism and clearance ANF during CHF and demonstrates cardiovascular and renal responses to C-ANF-(4-23) infusion in this pathophysiological condition characterized by elevated endogenous ANF.

AB - Atrial natriuretic factor (ANF) is a circulating 28-amino acid peptide that functions in the regulation of sodium homeostasis and vascular tone. ANF metabolism occurs via degradation by neutral endopeptidase 24.11 and binding to the ANF clearance receptor (ANFR-C). The present study was performed on anesthetized dogs, normal (control) and with experimental congestive heart failure (CHF), and was designed to investigate the ability of an ANF ligand specific for ANFR-C [C-ANF-(4-23)] to increase plasma ANF and also to evaluate the influence of ANFR-C on regional pulmonary and renal ANF clearances. C-ANF-(4-23) increased plasma ANF in controls (51 ± 15 to 123 ± 39 pg/ml; P < 0.05) and further increased plasma ANF in CHF dogs (242 ± 30 to 327 ± 34; P < 0.05), demonstrating that ANFR-C plays a significant role in the overall metabolism and clearance of ANF, even with chronically elevated ANF. Infusion of C-ANF-(4-23) produced a marked decrease in ANF pulmonary clearance (P(CL)ANF) in controls (1,018 ± 405 to -286 ± 383 ml/min; P < 0.05); however, P(CL)ANF was not altered by the ANF ligand in CHF dogs [-137 ± 174 to -106 ± 226 ml/min; not significant (NS)], suggesting an occupancy of ANFR-C or a downregulation of this receptor with chronically elevated plasma ANF. ANF renal clearance (R(CL)ANF) was not altered in either group by C-ANF-(4-23) infusion. Lack of change in P(CL)ANF and R(CL)ANF with ligand infusions during CHF suggests that the plasma ANF increase produced by C-ANF-(4-23) is related to an altered peptide clearance at sites other than the lung or kidney. This study demonstrates the contribution of ANFR-C to metabolism and clearance ANF during CHF and demonstrates cardiovascular and renal responses to C-ANF-(4-23) infusion in this pathophysiological condition characterized by elevated endogenous ANF.

KW - pulmonary clearance

KW - renal clearance

UR - http://www.scopus.com/inward/record.url?scp=0027248028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027248028&partnerID=8YFLogxK

M3 - Article

C2 - 8342659

AN - SCOPUS:0027248028

VL - 265

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 1 34-1

ER -